Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00822770 · ClinicalTrials.gov registry record · Phase 1
Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
NCT00822770: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00822770 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 47 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00822770, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn about the safety of AMD3100 (plerixafor) and G-CSF (filgrastim) in combination with fludarabine, busulfan, and an allogeneic blood stem cell transplant. This treatment will be studied in patients with acute myeloblastic leukemia (AML), myelodysplastic syndromes (MDS), or Chronic myelogenous leukemia (CML).
Interventions
- DRUG Fludarabine
- DRUG Busulfan
- DRUG Plerixafor
- DRUG Filgrastim
- PROCEDURE Allogeneic blood stem cell transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2009-01 |
| Est. Completion | 2012-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00822770
The ClinicalTrials.gov registry entry for NCT00822770 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Fludarabine is the first listed.
NCT00822770 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00822770 about?
NCT00822770 is a clinical study titled "Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin". The goal of this clinical research study is to learn about the safety of AMD3100 (plerixafor) and G-CSF (filgrastim) in combination with fludarabine, busulfan, and an allogeneic blood stem cell transplant. This treatment will be studied in patients with acute myeloblastic leukemia (AML), myelodyspla...
What is the current status of trial NCT00822770?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2009-01. Estimated completion is 2012-10.
What interventions are being tested in trial NCT00822770?
The interventions under investigation include: Fludarabine (DRUG), Busulfan (DRUG), Plerixafor (DRUG), Filgrastim (DRUG), Allogeneic blood stem cell transplant (PROCEDURE).
Who is sponsoring clinical trial NCT00822770?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.